Nano-X Imaging Ltd. - NNOX STOCK NEWS

Nanox (NASDAQ: NNOX) reported Q4 2024 financial results and business updates. The company generated $3.0 million in revenue, up from $2.4 million in Q4 2023. Key achievements include FDA clearance for Nanox.ARC general use and CE mark approval in the EU.

Financial highlights: Net loss increased to $14.1 million compared to $10.2 million in Q4 2023. The company reported a gross loss of $2.9 million. Cash position stood at $83.5 million as of December 31, 2024.

Business developments include new partnerships with Ezra AI Inc. for cancer detection screening and expansion into EU markets through distributors in Romania and Greece. The company raised approximately $37.8 million through the sale of 5.0 million ordinary shares in Q4 2024.

Nanox (NASDAQ: NNOX) announced that its subsidiary Nanox AI will present new data from the ADOPT study at four major medical conferences across Europe from March to June 2025. The study, completed in February 2025, evaluated HealthVCF at four NHS trusts in the UK.

Key findings show that HealthVCF analyzed 37,220 routine medical CT scans and identified over 3,450 new asymptomatic patients with vertebral compression fractures - up to six times more than the national NHS average. The AI-enabled Fracture Liaison Services demonstrated up to 10% reduction in patient refracture rates and cost savings of up to £50,000 per healthcare organization.

The company's newer FDA-cleared solution, HealthOST, offers improved fracture measurement precision and can detect low bone mineral density in routine CT scans without additional imaging or radiation exposure.

Nanox (NASDAQ: NNOX), a medical imaging technology company, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for March 31, 2025, before market open. The company will host a conference call at 8:30 a.m. ET featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel to discuss the results and provide a business update.

Nanox (NASDAQ: NNOX) will present new clinical data for its Nanox.ARC digital tomosynthesis system at ECR 2025 in Vienna. The system recently received both CE mark certification for European marketing and FDA 510(k) clearance in December 2024.

Three key studies will be presented:

• A 19-patient clinical study showing diagnostic value in 17 cases for fracture detection
• A phantom study demonstrating superior lung nodule detection in simulated obesity conditions compared to standard X-ray
• A case series highlighting improved musculoskeletal imaging applications

The Nanox.ARC system features a proprietary digital X-ray source with cold cathode technology, providing 3D body views while reducing radiation exposure and reading time. Clinical results showed enhanced detection of occult fractures, improved cast imaging, and potential reduction in CT scan requirements.

Nanox has received CE mark certification for its Nanox.ARC imaging system and Nanox.CLOUD infrastructure, enabling marketing in the European market. This follows the system's recent FDA clearance for general use in the U.S.

The Nanox.ARC is a stationary X-ray system that generates tomographic images using a proprietary digital X-ray source with cold cathode technology. It creates comprehensive 3D views of the body, enhancing visualization with multiple image layers while reducing structure super-imposition common in 2D X-rays.

Currently, there are dozens of units in various stages of shipment and deployment globally. The company will present new clinical data supporting Nanox.ARC usage at the European Congress of Radiology (ECR) 2025.

Nanox (NASDAQ: NNOX) has received FDA 510(k) clearance for its Nanox.ARC imaging system for general use, including pulmonary, intra-abdominal, and paranasal sinus indications, expanding from its previous musculoskeletal system clearance. The system features proprietary digital X-ray technology with cold cathode tomosynthesis, providing enhanced 3D visualization compared to traditional 2D X-rays.

The Nanox.ARC is currently deployed across seven U.S. states, with dozens of units in various stages of deployment worldwide. The system is designed for professional healthcare facilities and operated by trained medical professionals. It offers potential benefits including reduced patient wait times, faster diagnosis, and improved workflow integration, while requiring less space and power than traditional X-ray machines.

Nanox (NASDAQ: NNOX) reported Q3 2024 financial results with revenue of $3.0 million, up from $2.5 million in Q3 2023. The company posted a net loss of $13.6 million, improved from $21.4 million loss year-over-year. Teleradiology services generated $2.6 million in revenue with a 13% gross profit margin. The company continues expanding US sales teams and deploying units globally, while progressing with FDA applications for full body scanning and CE Mark designation. Cash position stands at $57.1 million as of September 30, 2024, down from $82.8 million at end of 2023.

Nanox (NASDAQ: NNOX) has announced it will release its third quarter 2024 financial results before market open on Thursday, November 21, 2024. The company will host a conference call at 8:30 a.m. ET, featuring CEO and Acting Chairman Erez Meltzer and CFO Ran Daniel, to discuss the results and provide a business update. Interested parties can access the call through registration and a live webcast, which will be available on the company's Investor Relations website.

Nanox AI, a subsidiary of NANO-X IMAGING (NNOX), has received a Special Mention in TIME's Best Inventions of 2024 list for its innovative medical imaging analytics solutions. The company's FDA-cleared AI technology analyzes routine CT scans to detect early signs of chronic conditions in cardiac, liver, and bone health. Their solutions include HealthCCSng for coronary artery calcification measurement, HealthOST for spine analysis, and HealthFLD for liver evaluation, all aimed at identifying previously undetected asymptomatic conditions to promote preventive care management.